Phaseline

Companies › Solid Biosciences

Solid Biosciences: clinical trials, targets and expected readouts

4 active drug programs in 5 registered trials: 4 Phase 1, 1 Phase 3; Neurology, Cardiovascular; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SGT-003
Adeno-associated virus serotype SLB101 gene therapy delivering human microdystrophin gene
DMDPhase 3Duchenne Muscular DystrophyMay 2027
SGT-001
AAV9 vector-mediated microdystrophin gene transfer
DMDPhase 1Duchenne Muscular DystrophyNov 2026
SGT-501
Gene therapy for ryanodine receptor 2 (RYR2) deficiency
RYR2Phase 1Catecholaminergic Polymorphic Ventricular TachycardiaJun 2027
SGT-212
Adeno-associated virus serotype AAVhu68 containing codon-optimized complementary DNA for F
FXNPhase 1Friedreich's Ataxia (FA)Mar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03368742SGT-001Phase 1Duchenne Muscular DystrophyNeurologyNov 2026
NCT06138639SGT-003Phase 1Duchenne Muscular DystrophyNeurologyMay 2027
NCT07148089SGT-501Phase 1Catecholaminergic Polymorphic Ventricular TachycardiaCardiovascularJun 2027
NCT07180355SGT-212Phase 1Friedreich's Ataxia (FA)NeurologyMar 2028
NCT07160634SGT-003Phase 3Duchenne Muscular DystrophyNeurologyJan 2029

From the company's SEC filings

Cash and short-term investments of $349m on 2026-09-30; operating cash outflow about $195m a year; runway about 22 months at that burn, to Jul 2028; 0 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 10 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

DMD (2) RYR2 (1) FXN (1)

Companies with the same targets

NS Pharma Sarepta Therapeutics Larimar Therapeutics Dyne Therapeutics Avidity Biosciences REGENXBIO Precision BioSciences Wave Life Sciences USA Belief BioMed (Beijing) Insmed Gene Therapy

Companies built like this

NS Pharma Larimar Therapeutics Denali Therapeutics Dyne Therapeutics Coya Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.